{"id":90918,"date":"2026-11-12T13:31:00","date_gmt":"2026-11-12T13:31:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=90918"},"modified":"2026-11-13T02:13:57","modified_gmt":"2026-11-13T02:13:57","slug":"biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/","title":{"rendered":"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials"},"content":{"rendered":"<p align=\"center\" style=\"text-align:center;\"><em>BD200 is a multibody drug conjugate, in which each arm of the antibody can alternatively bind to either Nectin-4 or Trop2, two\u00a0<\/em><em>validated oncology antigens that may be expressed on cancer cells<\/em><\/p>\n<p align=\"center\" style=\"text-align:center;\"><em>Combined with a unique linker and payload, BD200 can adapt to various local tumor expression profiles, and potentially overcome resistance<\/em><\/p>\n<p align=\"center\" style=\"text-align:center;\"><em>BD200\u2019s therapeutic index (TI) is estimated to be substantially greater than comparators<\/em><\/p>\n<p>WASHINGTON and NESS ZIONA, Israel, Nov.  12, 2026  (GLOBE NEWSWIRE) &#8212; Biolojic Design, a biotechnology company that uses AI to create antibodies that act as programmable, intelligent therapeutic candidates, today announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for BD200, a multibody drug conjugate that targets both Trop2 and Nectin-4. The IND clearance enables initiation of Biolojic\u2019s planned global Phase 1 clinical study in the United States focusing on patients with select solid tumors known to express Trop2 and Nectin-4.<\/p>\n<p>\u201cThe FDA\u2019s clearance of our IND for BD200 is a significant step toward advancing the first multibody into clinical testing,\u201d said Yanay Ofran, Ph.D., CEO and founder of Biolojic Design. \u201cIn addition to marking an important milestone in the evolution of multi-specific antibodies, it is also an important achievement in the application of AI to drug design by showing that AI can support the creation of antibodies with unique properties and potentially transformative capabilities. We look forward to starting our Phase 1 study in the coming weeks.\u201d<\/p>\n<p>\u201cAs we look to improve cancer treatment, the heterogeneity of tumor antigen expression and the development of resistance are significant challenges,\u201d said Roger Waltzman, M.D., Chief Medical Officer of Biolojic Design \u201cAs a multibody, BD200 has been designed to help overcome these hurdles with a flexible binding profile and a unique linker-payload profile that enables it to adapt to an individual patient\u2019s tumor expression, potentially improving efficacy and safety.\u201d<\/p>\n<p>Multibodies are standard-format, multi-specific antibodies in which each arm can alternatively bind to one or both of two targets. Targeting the validated oncology antigens Nectin-4 and Trop2, both of which may be expressed by a cancer cell, each arm of BD200 can individually bind to either antigen, with the goal of overcoming target expression heterogeneity and enabling BD200 to address a patient\u2019s specific tumor antigen expression profile.<\/p>\n<p><strong>The BD200 Phase 1 Clinical Study <\/strong><\/p>\n<p>The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BD200 in patients with tumors known to express these antigens. The study will be conducted in the U.S and globally. Once optimal biologic doses have been selected, the study will focus on one or more appropriate tumor types as well as potential monotherapy and combination therapy development pathways.<\/p>\n<p><strong>About BD200<\/strong><\/p>\n<p>BD200 is a multibody drug conjugate carrying a potent topoisomerase inhibitor payload that targets Trop2 and Nectin-4,\u00a0two antigens\u00a0that are expressed in a variety of solid tumors. As a multibody, BD200 can bind to Nectin-4 with both arms, Trop2 with both arms, or Trop2 with one arm and Nectin-4 with a second arm. In preclinical studies, BD200 was able to bind to both of these targets and adapt its specificity to the heterogeneous\u00a0antigen expression on tumor cells, increasing efficacy and\u00a0overcoming resistance when compared to standard monospecific antibody drug conjugates (ADCs) or a template bispecific ADC.<\/p>\n<p><strong>About Biolojic Design<\/strong><\/p>\n<p>Biolojic Design transforms antibodies into targeted drug candidates through AI and computational design. Biolojic\u2019s platform generated the first AI-designed antibody to enter the clinic, imneskibart, which is now in phase 2 clinical trials. Biolojic\u2019s platform turns human antibodies into multifunctional, programmable switches with specific functions: agonism, antagonism and conditional binding, enhancing their functionality and the precision of their effect. The company\u2019s pipeline focuses on autoimmune diseases and oncology, unlocking validated pathways that address large unmet needs. It is progressing its own pipeline and has partnerships with several leading biopharmaceutical companies to enhance its ability to bring important new therapeutic options to patients. For more information about Biolojic Design and its science and pipeline, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4yAFQp6SLd58mtWMq9RwC68wtwoovkjlo2Pn1_IM44eDI6YPKWWYmbNAk6Er-UIdmuS6W68q5yM-KhqTFK05e7sT_lz4hLJ9HvqvKg3a4oizVUIlyKxBMav_ssmFdr8nNDVufPZ_GOuTe3g_-Mn2OJXpeC-dsiY0GpCVcM6tWIRXJlSI8Hc14rZqT5fkTgdAc_kIMfXBU7cbcEycPJg_uOKRX9KhUIYaSyyAt5kFSyXLlf2M3XbP3JWQdkbSM09VhH8evjx7qN_PjW-CbWub6UGmrnFe57p3MmdIe28CYkIcOzpQpun-FhOF3YD1ruSGSubXYqll_1vaZeXgkYB_OIuNOBy_Ad7mpLcYjRtt1huVKGgBmiKWU8UjGH3ESIbGNgQ7Qcufe0vV06lzuo5-OXKUKuP55STzCJbjzzJUD4-qoUOWlC2xIOXQRvwkYR7SXktE2EUA_OrXQI81Zv0PhC3FG6vQl38DzFu6mdY9i8h0-yyPA42K8H0ij2hQgrU_\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/biolojic.com\/<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1YTRcDYjcPy5qlXgY0uvzvi-Fw5W6YbcufU4nGJRlpj6AOOvntHaYlDSH_ZMjKBGE11XUfHKHx0v4s0INMV2qVfkJ56M2dKjUL4cmOr1to2lS5WMWhI8pwgz8aqDx5XvIq9Bv6F1-3ssoWDAwNNWNdhDABaL0Wl1hvn_VLP87igaLXMawcyquWVmUTJB_kdI8_n0B0bym3VpnUL_cTEa31TyTuIkfqIuG8WWSqWssvYv8apaFcdhr0DT5WJrm9_ZPxChR3kmOAAJIfLDScun9SiGFoD1cY_ydG7GzMBiD2GIcShNtC9_3OabiHkMu8V_W_DsSQ0Yzh6adxJq_oqaSywIgGnaQpwii7dNPCuXB8SCuvp142j-TOixpt-dCkdZFAcjRENHJjuYQcTkTYay6ufp0eEHPEiDSEpCK3FTDKzCihrBOKr9Kq3IBf4G1pv2mDPEqKwiZxRgBNDorCSAEX-EuY2SY7fNGJgZLl4Mfdg=\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<p><strong>Media Contact<\/strong><\/p>\n<p>Todd Cooper<br \/>Biongage Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LtQSTQtH579gKRYN4a4gKWCaHdToCc29TFLRBmgJGaTEO6QSUFKhUAQiLyCor-AHIBnovDSxRro9Cv47Ep0Hxl05iY9VISsO_0YAm9xFifI=\" rel=\"nofollow\" target=\"_blank\" title=\"todd@biongage.com\">todd@biongage.com<\/a><\/p>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MGFlNDQzYWUtNGM3MC00ZGUwLTkzMDktYzBjMGNhMjhhNWFlLTEyMTkyMzYtMjAyNi0xMS0xMi1lbg==\/tiny\/Biolojic-Design.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BD200 is a multibody drug conjugate, in which each arm of the antibody can alternatively bind to either Nectin-4 or Trop2, two\u00a0validated oncology antigens that may be expressed on cancer cells Combined with a unique linker and payload, BD200 can adapt to various local tumor expression profiles, and potentially overcome resistance BD200\u2019s therapeutic index (TI) [&#8230;]\n","protected":false},"author":1,"featured_media":90919,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-90918","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"BD200 is a multibody drug conjugate, in which each arm of the antibody can alternatively bind to either Nectin-4 or Trop2, two\u00a0validated oncology ant\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T13:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-13T02:13:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials\",\"datePublished\":\"2026-11-12T13:31:00+00:00\",\"dateModified\":\"2026-11-13T02:13:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\"},\"wordCount\":702,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\",\"name\":\"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-12T13:31:00+00:00\",\"dateModified\":\"2026-11-13T02:13:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials","og_description":"BD200 is a multibody drug conjugate, in which each arm of the antibody can alternatively bind to either Nectin-4 or Trop2, two\u00a0validated oncology ant","og_url":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-12T13:31:00+00:00","article_modified_time":"2026-11-13T02:13:57+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials.gif","type":"image\/gif"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials","datePublished":"2026-11-12T13:31:00+00:00","dateModified":"2026-11-13T02:13:57+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/"},"wordCount":702,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/","url":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/","name":"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-12T13:31:00+00:00","dateModified":"2026-11-13T02:13:57+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/biolojic-design-receives-u-s-fda-clearance-of-investigational-new-drug-ind-application-for-bd200-the-first-multibody-to-enter-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=90918"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90918\/revisions"}],"predecessor-version":[{"id":90920,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90918\/revisions\/90920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/90919"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=90918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=90918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=90918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}